4-(1H-imidazol-1-yl)-3-methylaniline | 461664-00-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(1H-imidazol-1-yl)-3-methylaniline
• 英文别名: 4-imidazol-1-yl-3-methylaniline
• CAS: 461664-00-6
• 化学式: C₁₀H₁₁N₃
• mdl: MFCD11106415
• 分子量: 173.217
• InChiKey: IDERBIIMSOEWBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(1H-imidazol-1-yl)-3-methylaniline 在 palladium on activated charcoal 盐酸 、 硫酸 、 氢气 、 potassium nitrate 、 三乙胺 作用下， 以 氯仿 、 水 为溶剂， 25.0~60.0 ℃ 、101.33 kPa 条件下， 反应 1.5h， 生成 4-Imidazol-1-yl-5-methylbenzene-1,2-diamine
  参考文献：
  名称：

  Ohmori; Sakamoto; Kubota, Journal of Medicinal Chemistry, 1994, vol. 37, # 4, p. 467 - 475

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氟-5-硝基甲苯 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以 甲醇 为溶剂， 120.0 ℃ 、101.33 kPa 条件下， 反应 3.0h， 生成 4-(1H-imidazol-1-yl)-3-methylaniline
  参考文献：
  名称：

  Ohmori; Sakamoto; Kubota, Journal of Medicinal Chemistry, 1994, vol. 37, # 4, p. 467 - 475

  摘要：

  DOI：

文献信息

• Piperazine derivatives, their preparation and uses in therapy (5ht1b receptor activity)
  申请人：——

  公开号：US20040132720A1

  公开（公告）日：2004-07-08

  Compounds of formula (I) or a pharmaceutically acceptable salt thereof are disclosed: in which R a is a group of formula (i) wherein P 1 is phenyl, naphthyl or heteroaryl; R 1 is halogen, C 1-6 alkyl, C 3-6 cycloalkyl, COC 1-6 alkyl, C 1-6 alkoxy, hydroxy, hydroxyC 1-6 alkyl, nitro, haloC 1-6 alkyl, cyano, SR 6 , SOR 6 , SO 2 R 6 , SO 2 NR 6 R 7 , CO 2 R 6 , CONR 6 R 7 , OCONR 6 COR 7 , NR 6 r 7 , NR 6 COR 7 , NR 6 CO 2 R 7 , NR 6 SO 2 R 7 , NR 6 CONR 7 R 8 , CH 2 NR 6 COR 7 , CH 2 NR 6 CO 2 R 7 , CH 2 NR 6 SO 2 R 7 , CR 6 ═NOR 7 where R 6 , R 7 and R 8 are independently hydrogen or C 1-6 alkyl, a is 1, 1, 2, or 3; or R a is a group of formula (ii) where P 2 is phenyl, naphthyl, heteroaryl or a 5 to 7 membered heterocyclic ring; P 3 is phenyl, naphthyl or heteroaryl; R 2 is a defined above for R 1 in formula (I) or R 2 is heteroaryl optionally substituted By C 1 alkyl, halogen or COC 1-6 alkyl or is a 5-7 membered heterocyclic ring optionally substituted by oxo; R 3 is halogen, C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkyl, COC 1-6 alkyl, hydroxy, intro, haloC 1-6 alkyl, cyano, CO 2 R 6 , CONR 6 R 7 , NR 6 R 7 where R 6 and R 7 are as defined above; b and c are independently 0, 1, 2, or 3; Y is a single bond, CH 2 or NH; X is oxygen, sulfur or N—R 5 where R 5 is hydrogen or C 1-6 alkyl; R b is hydrogen, halogen, C 1-6 alkyl, haloC 1-6 alkyl, COC 1-6 alkyl or cyano; R c is hydrogen or C 1-6 alkyl. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy as 5-HT 1B receptor antagonists, for diseases such as depression, are also disclosed. 1

  公开了化学式（I）或其药学上可接受的盐的化合物：其中，R是式（i）的基团，其中P1是苯基、萘基或杂环基；R1是卤素、C1-6烷基、C3-6环烷基、COC1-6烷基、C1-6烷氧基、羟基、羟基C1-6烷基、硝基、卤C1-6烷基、氰基、SR6、SOR6、SO2R6、SO2NR6R7、CO2R6、CONR6R7、OCONR6COR7、NR6r7、NR6COR7、NR6CO2R7、NR6SO2R7、NR6CONR7R8、 NR6COR7、 NR6CO2R7、 NR6SO2R7、CR6═NOR7，其中R6、R7和R8独立地为氢或C1-6烷基，a为1、1、2或3；或R是式（ii）的基团，其中P2是苯基、萘基、杂环基或5-7成员的杂环环；P3是苯基、萘基或杂环基；R2是在式（I）中定义的R1或R2是杂环基，可选地被C1烷基、卤素或COC1-6烷基取代，或是5-7成员的杂环环，可选地被氧代取代；R3是卤素、C1-6烷基、C3-6环烷基、C1-6烷氧基、羟基、介绍、卤C1-6烷基、氰基、CO2R6、CONR6R7、NR6R7，其中R6和R7如上所述；b和c独立地为0、1、2或3；Y是单键、CH2或NH；X是氧、硫或N-R5，其中R5是氢或C1-6烷基；Rb是氢、卤素、C1-6烷基、卤C1-6烷基、COC1-6烷基或氰基；Rc是氢或C1-6烷基。还公开了其制备方法、含有它们的药物组合物以及它们在治疗抑郁等疾病中作为5-HT1B受体拮抗剂的用途。
• Per-6-amino-β-cyclodextrin as an Efficient Supramolecular Ligand and Host for Cu(I)-Catalyzed <i>N</i>-Arylation of Imidazole with Aryl Bromides
  作者：Palaniswamy Suresh、Kasi Pitchumani

  DOI：10.1021/jo801811w

  日期：2008.11.21

  Per-6-amino-beta-cyclodextrin (per-6-ABCD), acting simultaneously as a supramolecular ligand for CuI and host for aryl bromides, catalyzes N-arylation of imidazole with aryl bromides under mild conditions. This simple method proceeds with excellent yield for the coupling of imidazole with various substituted aryl bromides demonstrating good tolerance of other functionalities.
• PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USES IN THERAPY (5HT1B RECEPTOR ACTIVITY)
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1368344A1

  公开（公告）日：2003-12-10
• [EN] PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USES IN THERAPY (5HT1B RECEPTOR ACTIVITY)<br/>[FR] DERIVES DE PIPERAZINE, LEUR PREPARATION ET LEURS UTILISATIONS THERAPEUTIQUES (ACTIVITE DU RECEPTEUR 5HT1B)
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2002074768A1

  公开（公告）日：2002-09-26

  Compounds of formula (I) or a pharmaceutically acceptable salt thereof are disclosed: in which Ra is a group of formula (i) wherein P1 is phenyl, naphthyl or heteroaryl; R1 is halogen, C¿1-6?alkyl, C3-6cycloalkyl, COC1-6alkyl, C1-6alkoxy, hydroxy, hydroxyC1-6alkyl, nitro, haloC1-6alkyl, cyano, SR?6, SOR6, SO¿2R6, SO2NR6R7, CO2R?6, CONR6R7, OCONR6COR7, NR6r7, NR6COR7, NR6CO¿2R?7, NR6SO¿2R?7, NR6CONR7R8, CH¿2NR?6COR7, CH¿2NR6CO2R7, CH2NR6SO2R?7, CR6=NOR7¿ where R?6, R7 and R8¿ are independently hydrogen or C¿1-6?alkyl, a is 1, 1, 2, or 3; or R?a¿ is a group of formula (ii) where P2 is phenyl, naphthyl, heteroaryl or a 5 to 7 membered heterocyclic ring; P3 is phenyl, naphthyl or heteroaryl; R2 is a defined above for R1 in formula (I) or R2 is heteroaryl optionally substituted By C¿1-6?alkyl, halogen or COC1-6alkyl or is a 5-7 membered heterocyclic ring optionally substituted by oxo; R?3¿ is halogen, C¿1-6?alkyl, C3-6cycloalkyl, C1-6alkyl, COC1-6alkyl, hydroxy, intro, haloC1-6alkyl, cyano, CO2R?6, CONR6R7, NR6R7¿ where R?6 and R7¿ are as defined above; b and c are independently 0, 1, 2, or 3; Y is a single bond, CH¿2? or NH; X is oxygen, sulfur or N-R?5¿ where R5 is hydrogen or C¿1-6?alkyl; R?b¿ is hydrogen, halogen, C¿1-6?alkyl, haloC1-6alkyl, COC1-6alkyl or cyano; R?c¿ is hydrogen or C¿1-6?alkyl. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy as 5-HT1B receptor antagonists, for diseases such as depression, are also disclosed.